Savant Capital Lowers stake in DexCom (DXCM)

DexCom (DXCM) : Savant Capital reduced its stake in DexCom by 0.85% during the most recent quarter end. The investment management company now holds a total of 44,081 shares of DexCom which is valued at $2.7 Million after selling 380 shares in DexCom , the firm said in a disclosure report filed with the SEC on May 11, 2016.DexCom makes up approximately 0.83% of Savant Capital’s portfolio.

Other Hedge Funds, Including , Menta Capital added DXCM to its portfolio by purchasing 10,000 company shares during the most recent quarter which is valued at $606,300. DexCom makes up approx 0.08% of Menta Capital’s portfolio.Pier Capital reduced its stake in DXCM by selling 25,855 shares or 39.03% in the most recent quarter. The Hedge Fund company now holds 40,387 shares of DXCM which is valued at $2.5 Million. DexCom makes up approx 0.49% of Pier Capital’s portfolio.J&p(china)capital Managementltd reduced its stake in DXCM by selling 100,115 shares or 49.24% in the most recent quarter. The Hedge Fund company now holds 103,200 shares of DXCM which is valued at $6.3 Million. DexCom makes up approx 1.90% of J&p(china)capital Managementltd’s portfolio.Calvert Investment Management boosted its stake in DXCM in the latest quarter, The investment management firm added 180 additional shares and now holds a total of 4,535 shares of DexCom which is valued at $278,041. DexCom makes up approx 0.01% of Calvert Investment Management’s portfolio.

DexCom opened for trading at $60.95 and hit $62.95 on the upside on Monday, eventually ending the session at $62.8, with a gain of 3.58% or 2.17 points. The heightened volatility saw the trading volume jump to 8,86,618 shares. Company has a market cap of $5,240 M.

On the company’s financial health, DexCom reported $-0.23 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 27, 2016. Analyst had a consensus of $-0.21. The company had revenue of $116.20 million for the quarter, compared to analysts expectations of $110.93 million. The company’s revenue was up 59.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.

Many Wall Street Analysts have commented on DexCom. Shares were Reiterated by The Benchmark Company on Feb 24, 2016 to “Buy” and Lowered the Price Target to $ 86 from a previous price target of $105 .

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.